Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. doi:10.1056/NEJMoa1003466.
CAS
Article
PubMed
PubMed Central
Google Scholar
Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–94. doi:10.1200/JCO.2014.56.2736.
CAS
Article
PubMed
PubMed Central
Google Scholar
Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26. doi:10.1056/NEJMoa1104621.
CAS
Article
PubMed
Google Scholar
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–32. doi:10.1056/NEJMoa1503093.
CAS
Article
PubMed
Google Scholar
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–17. doi:10.1056/NEJMoa1414428.
Article
PubMed
Google Scholar
Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:1270–1. doi:10.1056/NEJMc1509660.
Article
PubMed
Google Scholar
Wang AX, Qi XY. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma. IUBMB Life. 2013;65:748–58. doi:10.1002/iub.1193.
CAS
Article
PubMed
Google Scholar
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16. doi:10.1056/NEJMoa1103782.
CAS
Article
PubMed
PubMed Central
Google Scholar
McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323–32. doi:10.1016/S1470-2045(14)70012-9.
CAS
Article
PubMed
PubMed Central
Google Scholar
Beale S, Dickson R, Bagust A, Blundell M, Dundar Y, Boland A, et al. Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal. Pharmacoeconomics. 2013;31:1121–9. doi:10.1007/s40273-013-0094-x.
Article
PubMed
Google Scholar
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–65. doi:10.1016/S0140-6736(12)60868-X.
CAS
Article
PubMed
Google Scholar
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. An update on overall survival (OS) and follow-on therapies in BREAK-3, a phase III, randomized trial: dabrafenib (D) versus dacarbazine (DTIC) in patients (pts) with BRAF V600E mutation-positive metastatic melanoma (MM). Presented at the European Society for Medical Oncology Annual Meeting, 29 September 2014. 2014. http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Melanoma-and-Other-Skin-Tumours/An-update-on-overall-survival-OS-and-follow-on-therapies-in-BREAK-3-a-Phase-III-randomized-trial-dabrafenib-D-vs.-dacarbazine-DTIC-in-patients-pts-with-BRAF-V600E-mutation-positive-metastatic-melanoma-MM. Accessed 16 August 2016.
Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, et al. A landmark analysis of 3-year overall survival (OS) and follow-on therapies in BREAK-3, a phase III, randomized trial: dabrafenib versus dacarbazine (DTIC) in patients (pts) with BRAF V600E mutation-positive metastatic melanoma. 2014 Society for Melanoma Research Annual Meeting. Zurich, Switzerland. 2014.
Latimer NR, Abrams KR, Amonkar MM, Stapelkamp C, Swann RS. Adjusting for the confounding effects of treatment switching-the BREAK-3 trial: dabrafenib versus dacarbazine. Oncologist. 2015;20:798–805. doi:10.1634/theoncologist.2014-0429.
Article
PubMed
PubMed Central
Google Scholar
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107–14. doi:10.1056/NEJMoa1203421.
CAS
Article
PubMed
Google Scholar
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9. doi:10.1056/NEJMoa1412690.
Article
PubMed
Google Scholar
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877–88. doi:10.1056/NEJMoa1406037.
Article
PubMed
Google Scholar
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386:444–51. doi:10.1016/S0140-6736(15)60898-4.
CAS
Article
PubMed
Google Scholar
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694–703. doi:10.1056/NEJMoa1210093.
CAS
Article
PubMed
PubMed Central
Google Scholar
Flaherty K, Daud A, Weber J, Sosman J, Kim K, Gonzalez R, et al. Updated overall survival for BRF113220: a phase 1–2 study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 mutation-positive metastatic melanoma. J Clin Oncol. 2014;32:Abstract 9010. http://meetinglibrary.asco.org/content/134903-144. Accessed 16 August 2016.
Daud A, Weber J, Sosman J, Kim K, Gonzalez R, Hamid O, et al. Updated overall survival for BRF113220: a phase 1–2 study of dabrafenib alone vs combined dabrafenib and trametinib in patients with BRAF V600 mutation-positive metastatic melanoma. J Clin Oncol. 2015;33:Abstract 9036. http://meetinglibrary.asco.org/content/147629-156. Accessed 16 August 2016.
Srivastava K, Amonkar MM, Ahuja A, Stapelkamp C, Swann S, Casey M, et al. Systematic review and indirect treatment comparison of dabrafenib and trametinib versus other treatments used in previously untreated metastatic melanoma patients. J Clin Exp Dermatol Res. 2015;6:13. doi:10.4172/2155-9554.1000294.
Article
Google Scholar
National Institute for Health and Care Excellence. Melanoma (BRAF V600E mutation positive, unresectable, metastatic)—dabrafenib and trametinib [ID661]. 2016. https://www.nice.org.uk/guidance/indevelopment/gid-tag365. Accessed 16 August 2016.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. doi:10.1136/bmj.b2700.
Article
PubMed
PubMed Central
Google Scholar
Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33:1191–6. doi:10.1200/JCO.2014.56.6018.
CAS
Article
PubMed
Google Scholar
Latimer NR, Amonkar MM, Stapelkamp C, Sun P. Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma. Melanoma Res. 2015;25:528–36. doi:10.1097/CMR.0000000000000193.
CAS
Article
PubMed
Google Scholar
Latimer NR, Bell H, Abrams KR, Amonkar MM, Casey M. Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy. Cancer Med. 2016;. doi:10.1002/cam4.643.
PubMed
PubMed Central
Google Scholar
Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33:607–17. doi:10.1177/0272989X12458724.
Article
PubMed
PubMed Central
Google Scholar
Achana FA, Cooper NJ, Bujkiewicz S, Hubbard SJ, Kendrick D, Jones DR, et al. Network meta-analysis of multiple outcome measures accounting for borrowing of information across outcomes. BMC Med Res Methodol. 2014;14:92. doi:10.1186/1471-2288-14-92.
Article
PubMed
PubMed Central
Google Scholar
Flaherty KT, Hennig M, Lee SJ, Ascierto PA, Dummer R, Eggermont AM, et al. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol. 2014;15:297–304. doi:10.1016/S1470-2045(14)70007-5.
Article
PubMed
PubMed Central
Google Scholar
Mai R, Zhou S, Zhong W, Rong S, Cong Z, Li Y, et al. Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials. Oncotarget. 2015;6:28502–12. doi:10.18632/oncotarget.4375.
Article
PubMed
PubMed Central
Google Scholar
Cope S, Jansen JP. Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making. BMC Med Res Methodol. 2013;13:147. doi:10.1186/1471-2288-13-147.
Article
PubMed
PubMed Central
Google Scholar
Jansen JP, Cope S. Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes. BMC Med Res Methodol. 2012;12:152. doi:10.1186/1471-2288-12-152.
Article
PubMed
PubMed Central
Google Scholar
Dequen P, Lorigan P, Jansen JP, van Baardewijk M, Ouwens MJ, Kotapati S. Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. Oncologist. 2012;17:1376–85. doi:10.1634/theoncologist.2011-0427.
CAS
Article
PubMed
PubMed Central
Google Scholar
Ouwens MJ, Philips Z, Jansen JP. Network meta-analysis of parametric survival curves. Res Synth Methods. 2010;1:258–71. doi:10.1002/jrsm.25.
Article
PubMed
Google Scholar
Hersh EM, O’Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs. 2011;29:489–98. doi:10.1007/s10637-009-9376-8.
CAS
Article
PubMed
Google Scholar
Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204. doi:10.1186/1479-5876-9-204.
CAS
Article
PubMed
PubMed Central
Google Scholar
Squibb B-M. An exploratory study to determine potential predictive markers of response and/or toxicity in patients with unresectable stage III or IV malignant melanoma randomized and treated with ipilimumab (MDX-010/BMS-734016) at two dose levels. http://ctr.bms.com/pdf/CA184-004ST.pdf. Accessed 16 August 2016.
Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155–64. doi:10.1016/S1470-2045(09)70334-1.
CAS
Article
PubMed
Google Scholar
Squibb B-M. A randomized, double-blind, multi-center, phase II fixed dose study of multiple doses of ipilimumab (MDX-010) monotherapy in patients with previously treated unresectable stage III or IV Melanoma. Final Clinical Study Report for Study CA184022. http://ctr.bms.com/pdf/CA184-022%20ST.pdf. Accessed 16 August 2016.
Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29:1239–46. doi:10.1200/JCO.2010.32.4327.
Article
PubMed
Google Scholar
Thomas NE, Edmiston SN, Alexander A, Groben PA, Parrish E, Kricker A, et al. Association between NRAS and BRAF mutational status and melanoma-specific survival among patients with higher-risk primary melanoma. JAMA Oncol. 2015;1:359–68. doi:10.1001/jamaoncol.2015.0493.
Article
PubMed
PubMed Central
Google Scholar
Menzies AM, Long GV. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. Eur J Cancer. 2013;49:3229–41. doi:10.1016/j.ejca.2013.06.027.
CAS
Article
PubMed
Google Scholar
Hugdahl E, Kalvenes MB, Puntervoll HE, Ladstein RG, Akslen LA. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival. Br J Cancer. 2016;114:801–8. doi:10.1038/bjc.2016.44.
CAS
Article
PubMed
Google Scholar
Ugurel S, Thirumaran RK, Bloethner S, Gast A, Sucker A, Mueller-Berghaus J, et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One. 2007;2:e236. doi:10.1371/journal.pone.0000236.
Article
PubMed
PubMed Central
Google Scholar
Moreau S, Saiag P, Aegerter P, Bosset D, Longvert C, Helias-Rodzewicz Z, et al. Prognostic value of BRAF(V(6)(0)(0)) mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol. 2012;19:4314–21. doi:10.1245/s10434-012-2457-5.
Article
PubMed
Google Scholar
Nowara E, Nieckula J, Badora-Rybicka A, Rajczykowski M, Huszno J. Impact of BRAF V600 mutation in metastatic cutaneous melanoma patients treated with systemic therapy on brain metastases and survival. Pigment Cell Melanoma Res. 2015;28:803. doi:10.1111/pcmr.12419.
Google Scholar